Tegatrabetan

Drug Profile

Tegatrabetan

Alternative Names: BC-2059

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator BetaCat Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Fibroma; Multiple myeloma

Most Recent Events

  • 10 Feb 2017 BetaCat Pharmaceuticals plans clinical studies in Fibroma and Acute myeloid leukaemia in the first half of 2017 (BetaCat Pharmaceuticals pipeline, February 2017)
  • 03 Dec 2016 Pharmacodynamic data from preclinical studies in Multiple myeloma presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016) .
  • 01 Jun 2016 Preclinical trials in Acute myeloid leukaemia, Fibroma, Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top